Abstract:

Since the report of the utilization of botulinum toxin type A (BTA) in treatment of strabismus in the 1970s, there were countless attempts and extensive applications of BTA in the treatment field of ophthalmic diseases such as strabismus, blepharospasm, eyelid retraction, entropion, lacrimal hypersecretion, nystagmus, due to its less trauma and side effects. Especially in the field of concomitant strabismus, it is a research hotspot. The efficacy  of BTA  in children's concomitant strabismus is still controversial. Complications are uncommon and are mostly transient, often occurring in relation to the position, dose and technique of injection. （Int Rev Ophthalmol, 2018, 42: 381-387）